Many industrial and pharmaceutical processes require enzymes capable of producing one desired stereoisomer with exceptional selectivity. Small changes in enzyme structure can dramatically influence product configuration, reaction efficiency, downstream purification, and regulatory acceptance.
Neoncorte Bio combines artificial intelligence, computational protein engineering, and machine learning to engineer enzymes with improved enantioselectivity and stereoselectivity while maintaining catalytic activity, stability, expression, and manufacturability.
Our computational workflows accelerate Design-Build-Test-Learn (DBTL) cycles by identifying promising variants before laboratory validation.